Neuroscience

#Alzheimer's #Business #Immunology / Virology & Vaccines #Oncology

This week in drug discovery (8-12 August)  

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer… Read More

#News

#Alzheimer's #Collaboration #Neurology #US

Cerevance teams up with Merck (MSD) on Alzheimer’s project  

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   Cerevance will receive an upfront payment of $25 million from Merck (MSD) and could receive development and commercial milestone payments of up to… Read More

#News

#Alzheimer's #Biogen #EIT Health #Neurology

Start-ups win EU-pharma Alzheimer’s contest  

Two start-ups have won a competition organised by EIT Health and pharmaceutical company Biogen which aimed at identifying solutions for Alzheimer’s disease.   French start-up Five Lives and Dutch start-up Neurocase were respectively placed first and second in the ‘neurotechprize’ competition. The winners were announced during a ceremony… Read More

#News

#Alzheimer's #Biotechnology #Mouse models #Neurodegenerative disorders

Novel drug effective in a mouse model of Alzheimer’s disease

Neuro-Bio, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, has found its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease. Publishing their work in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI)… Read More

#News

#Alzheimer's #Genetics / genomes

Scientists uncover new genetic factors for Alzheimer’s disease  

Scientists have discovered 75 genetic risk factors for Alzheimer’s disease in research which could help with the development of new therapies.   An international group of scientists from Inserm, Institut Pasteur de Lille, Lille University Hospital, and Université de Lille and the University of Bristol… Read More

#News

#Alzheimer's #Clinical trials #Pharma

Winterlight Labs launches speech assessment collaboration  

Digital biomarkers developer Winterlight Labs and memory clinic Alzheimer Center Amsterdam will work together on a project to decentralise assessments of patients’ cognition and function in the study of preclinical Alzheimer’s disease.   The project will see Alzheimer Center Amsterdam develop a remote measurement toolbox, integrating Winterlight’s digital… Read More

#News

#Mass spectrometry / NMR #Neurodegenerative disorders

Separating ganglioside isomers using HRIM–MS

In this article, Komal Kedia (Senior Scientist at Merck), Rena Zhang (Senior Scientist at Merck), Weixun Wang (Senior Scientist at Merck), Kevin Bateman (Scientific Associate VP at Merck) and Kelly Moser (Applications Manager at MOBILion Systems) show how ganglioside isomers with suspected roles in neurodegenerative diseases can be separated… Read More

#Editor's Choice #Exclusive Content #News

FDA
#Drug approvals #Parkinson's #Pharmaceuticals

First live biotherapeutic approved to treat Parkinson’s disease 

The US Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for MRx0005 and MRx0029, two 4D Pharma Live Biotherapeutics (LBPs). The company expects to initiate a first-in-human Phase I clinical trial in people with Parkinson’s disease in mid-2022.  Context  Parkinson’s disease… Read More

#News

#Collaboration #Drug therapy #Neuroscience #Parkinson's

Collaboration targeting neuroinflammation to slow Parkinson’s  

Parkinson’s UK and Domainex have collaborated to develop small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s Disease.   Context  Inflammation is vital for defending the body from infections, injuries and toxins. However, in Parkinson’s there is excessive chronic inflammation within the brain. Read More

#News

#Antibodies #Biotechnology #Collaboration #Neurodegenerative disorders #Neuroscience

Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach.  Background  In November 2017, Ono and Neurimmune signed… Read More

#News

#Alzheimer's #Events #Neuroscience

AlzeCure gets late-breaking neuroscience abstract accepted  

AlzeCure Pharma, a pharmaceutical company that develops small molecule candidate drugs for diseases affecting the central nervous system, has announced that an abstract on clinical data of its candidate drug ACD856 has been accepted for a poster presentation at AD/PD 2022, which this year will be held in Barcelona on… Read More

#News

#Biotechnology #Microbiome #Neuroscience

Gut-brain research could result in improved cognitive performance 

In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers.  The study … Read More

#News

#Biosciences #Drug targets #Neuroscience #Schizophrenia

Collaboration to develop treatment for neuropsychiatric disorders 

Neurocrine Biosciences and Sosei Group Corporation have collaborated to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.  The agreement terms  Under the terms of the agreement, Neurocrine Biosciences gains development and commercialisation rights to… Read More

#News

Human brain
#Drug development #Drug discovery #Healthcare #Neuroscience #Pharmaceuticals

NICE approves drug which treats EDS caused by narcolepsy 

Jazz Pharmaceuticals’ Sunosi (solriamfetol) has been issued a positive Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE), recommending the drug for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1  When is solriamfetol needed?  Solriamfetol is recommended as an option for treating EDS… Read More

#News #Trending News

#Imaging #Neuroscience #Neurotechnology #Technology

Inscopix showcases new brain mapping technology 

Inscopix, a brain mapping platform company developing neurotechnologies for improved disease treatments, displayed the latest product and research innovations around its miniature microscope-based neural circuitry technology at the 50th annual meeting of the Society for Neuroscience (SfN), which was held virtually November 8-11.  Showcasing new technologies that enable… Read More

#News

#Drug development #Neuroscience #Therapeutics

Appointment seeks to boost brain disorder therapy development 

Inscopix, a brain mapping platform, appointed David Gray as Chief Scientific Officer (CSO) in a new position to discover and develop more effective therapies for brain disorders.  Inscopix provides brain research tools to basic and translational researchers in academia as well as biotech and pharma companies in neuroscience. Read More

#News